|
Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models. |
|
|
No Relationships to Disclose |
|
|
Employment - Cleave Biosciences; ESSA |
Stock and Other Ownership Interests - Cleave Biosciences; ESSA |
Patents, Royalties, Other Intellectual Property - Cleave Biosciences; ESSA |
Travel, Accommodations, Expenses - Cleave Biosciences; ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
Consulting or Advisory Role - ESSA |
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
|
Stock and Other Ownership Interests - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
Travel, Accommodations, Expenses - ESSA |
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
|
|
|
Stock and Other Ownership Interests - ESSA |
Consulting or Advisory Role - ESSA |
|
Patents, Royalties, Other Intellectual Property - ESSA |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - ESSA |